Objective: This study evaluated the association between magnesium sulfate treatment for fetal neuroprotection on APRI scores in pregnant women with the preterm birth threat.
Matherials and Methods: Thirty-one pregnant women who received neuroprotective magnesium sulfate between 2019-2022 were retrospectively evaluated. Pregnancies with other comorbidities or obstetric complications were excluded. The hemogram and biochemical analyses applied before and after a loading dose of magnesium sulfate were compared.
Results: The mean APRI score at the 12th hour of administration (0.45±0.07) was significantly higher than the basal values (0.31±0.07) (p0.05 for all).
Conclusion: Magnesium sulfate treatment for preterm birth threat significantly increases APRI score at the 12th hour of administration.